Agilent Technologies (NYSE:A) Price Target Raised to $180.00

Agilent Technologies (NYSE:A) had its price target lifted by research analysts at TD Cowen from $155.00 to $180.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. TD Cowen’s target price indicates a potential upside of 14.30% from the company’s previous close.

A number of other research firms have also recently commented on A. Piper Sandler assumed coverage on Agilent Technologies in a research note on Thursday, June 11th. They set a “neutral” rating and a $150.00 target price on the stock. Royal Bank Of Canada raised their price target on Agilent Technologies from $155.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday. Robert W. Baird boosted their price objective on Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a report on Tuesday, May 26th. Wolfe Research reaffirmed a “hold” rating on shares of Agilent Technologies in a research report on Tuesday, June 2nd. Finally, Wells Fargo & Company reduced their target price on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $165.06.

Agilent Technologies Trading Up 1.5%

A stock traded up $2.40 during mid-day trading on Thursday, reaching $157.48. 1,033,014 shares of the stock traded hands, compared to its average volume of 2,227,299. Agilent Technologies has a one year low of $108.35 and a one year high of $163.75. The stock has a market capitalization of $44.48 billion, a PE ratio of 31.63, a PEG ratio of 2.73 and a beta of 1.25. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10. The business has a 50-day moving average price of $139.16 and a two-hundred day moving average price of $126.65.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. The firm had revenue of $1.88 billion during the quarter, compared to analysts’ expectations of $1.84 billion. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The firm’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Equities research analysts expect that Agilent Technologies will post 6.05 EPS for the current year.

Institutional Trading of Agilent Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in A. Brighton Jones LLC raised its position in Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after purchasing an additional 270 shares during the period. Jones Financial Companies Lllp lifted its position in Agilent Technologies by 15.9% in the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company’s stock valued at $602,000 after buying an additional 769 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in Agilent Technologies by 54.8% during the first quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company’s stock worth $70,000 after buying an additional 212 shares during the period. Acadian Asset Management LLC boosted its stake in Agilent Technologies by 16.5% during the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company’s stock worth $625,000 after buying an additional 758 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in Agilent Technologies during the second quarter worth about $273,000. Institutional investors and hedge funds own 87.41% of the company’s stock.

Agilent Technologies News Summary

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Quarterly results exceeded expectations. Agilent reported revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted earnings were $1.62 per share, versus expectations of $1.49, while reported net income rose to $362 million from $336 million a year earlier. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: Profitability and cash generation improved. Operating profit increased 23.3% to $444 million, and operating cash flow climbed 43.4% to $519 million. The results suggest expanding margins and stronger execution, supporting the positive market reaction. Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance
• Positive Sentiment: Agilent raised its fiscal 2026 forecast. The company now expects full-year adjusted EPS of $6.18-$6.21, above the approximately $6.06 consensus, and revenue of about $7.5 billion, also ahead of expectations. Fourth-quarter EPS guidance of $1.71-$1.74 is at or above estimates. Management cited improving demand for medical, laboratory and drug-development equipment. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Royal Bank of Canada raised its price target. RBC lifted its target from $155 to $185 and reaffirmed an “outperform” rating, providing additional analyst support following the earnings beat. Benzinga
• Neutral Sentiment: At roughly $158 per share, Agilent is trading near its 52-week high and at a reported P/E ratio above 31, indicating that investors are already assigning a premium to the company’s improving growth outlook.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.